Efficacy of parent-mediated communication-focused treatment in toddlers with autism (PACT) delivered via videoconferencing: a randomised controlled trial study protocol

Lucie Jurek,1,2 Pauline Occelli,2,3 Angelique Denis,3 Anouck Amestoy,4 Thierry Maffre,5 Tom Dauchez,4 Marie-Joelle Oreve,6 Amania Baghdadi,7,8 Carmen Schroder,9,10 Agathe Jay,7 Amélie Zelmar,2,3 Anne Revah-Levy,11,12 Natacha Gallifet,1 Catherine aldered,13 Shruti Garg,14 Jonathan Green,14,15 Sandrine Touzet,2,3 Marie-Maude Geoffray,1,2 On behalf of IFPAD study group

ABSTRACT

Introduction Intervention in the preschool period is currently recommended for autism spectrum disorder. Therapies delivered by parents are particularly suitable for young children. Preschool Autism Communication Trial (PACT) is a parent-mediated therapy that has shown a significant and sustained impact on autism symptom reduction. However, access to such evidence-based therapies for families is limited due to autism centres located in large urban areas. Using videoconferencing to deliver PACT training to parents may improve accessibility for families living in underserved areas.

Methods and analysis This single-blind randomised controlled trial, involving six sites in France, will investigate the efficacy of a telehealth, videoconferencing-based, parent-mediated PACT therapy on autism symptoms, over a 12-month period. It will compare PACT plus treatment as usual (TAU) against TAU only in a cohort of 238 toddlers (119 per group) aged 18–36 months at inclusion and living with their families more than 40 min away from the specialist centres for autism. Primary outcome will include change of overall autism score on the Autism Diagnostic Observation Scale (ADOS) at 12 months. Secondary outcomes will measure change in child skills, child functioning, impact on parents (stress, health, priorities) and implementation characteristics. Repeated measures analyses will be used to test the effect of PACT intervention on the overall ADOS module 1 score over the 12-month study period. Linear mixed models will be used with time, treatment allocation and the interaction between treatment and time as fixed effects and individual variation as random effect.

Ethics and dissemination This protocol (v5, date: 25 October 2019) is approved by the French National Review Board (reference no 2018-A02516-49). The results will be disseminated via peer-reviewed journals.

Trial registration number NCT04244721.

INTRODUCTION

Rationale and background

Autism spectrum disorder (ASD) is a common neurodevelopmental disorder with a population prevalence of at least 1.5% in developed countries and can cause significant lifelong disability1–3 and burden for families and caregivers.4 Diagnosis is possible as early as 18 months of age.5 Current evidence suggests that interventions delivered in the early developmental period before the age of 3 years has the potential for maximal impact on autism symptom severity.

Therapies can be delivered by therapists, teachers and parents.6 For preschool children with ASD, parent-mediated therapies can guide parents to face challenging social interaction with their children.7,8 Among the different parent-mediated therapies, Preschool Autism Communication Trial...
(PACT) has shown significant short and long-term efficacy on objectively assessed autism symptoms in children aged from 2 to 10 years in a large UK cohort (N=152); as showed in a recent systematic review and meta-analysis. In PACT, parents are guided by a therapist via video feedback to optimise parent–child dyadic interaction, which in turn impacts on child language, communication and autism symptoms. In a trial of PACT intervention compared with regular care, PACT showed a statistically significant effect at 13-month endpoint to reduce of autism symptom severity measured on Autism diagnostic Observation Schedule version 2 (ADOS-2) (effect size 0.64; 95% CI 0.07 to 1.20); and an increase in parental communication synchrony with the child and child communication initiations with the parent. The follow-up study showed evidence of sustained effect on autism symptom severity 6 years after intervention end, with a significant overall reduction in symptom severity over the course of trial and follow-up period (effect size=0.55, 95% CI 0.14 to 0.91, p=0.004). A mechanistic study also confirmed that the distal effect of PACT therapy on autism severity measured by ADOS was mediated by the improvement of child communication initiations, which in turn was mediated by improved parent–child synchrony.

Availability of PACT therapy is limited; even more so in rural settings or in regions away from specialist centres. Using videoconferencing run by therapists to train parents in PACT may, therefore, be a viable alternative to make such therapies available to families living far from autism centres. Previous studies have shown that it is possible to provide parent-mediated therapies in autism by videoconferencing successfully. The team who developed the PACT therapy reported positive experiences of parent guidance by videoconferencing (C. Aldred and J. Green, personal communication, June 10, 2020). Indeed, videoconferencing was used to deliver some of the PACT sessions in a recently published randomised controlled trial (RCT). However, PACT has never been evaluated when exclusively delivered by videoconferencing. The barriers and facilitators to delivering such therapies via videoconferencing are not sufficiently well understood, and hence it is essential to investigate and address them adequately.

Research question: The proposed protocol is for a large RCT in children under 3 years with ASD to evaluate the effectiveness on autistic symptom severity and other measures of PACT therapy delivered to parents by videoconferencing. A significant effect would justify and facilitate the routine use of videoconferencing therapy in early intervention and improve the dissemination of this evidence-based practice.

The hypothesis is that PACT intervention delivered by videoconferencing+treatment as usual (TAU) will have a superior efficacy on child autism symptom severity as compared with TAU alone.

Objectives
Our primary objective will be to test the efficacy of a parent-mediated PACT therapy, delivered by trained therapists to parents living in underserved areas via videoconferencing over a 12-month period, on overall autistic symptoms in children with ASD aged from 18 to 36 months at inclusion, measured using the ADOS-2.

Our secondary objectives will include an evaluation of change in child sociocommunicative interactions, language, communication initiation and daily adaptive behaviour. At the parent level, we will evaluate the intervention effects on stress, health and family functioning.

The implementation of the therapy will be evaluated through the adherence of professionals and parents to PACT, and acceptability and feasibility of the PACT sessions to parents and therapists.

METHOD
Study design
This is a prospective multicentre RCT with two parallel group, 1:1 ratio, single-blind comparing PACT intervention+TAU against TAU alone. Evaluation will be carried out using quantitative and qualitative mixed-method approaches.

Semistructured interviews with parents and therapists will be conducted to understand the barriers and facilitators of using the videoconferencing approaches to delivering the PACT therapy.

Figure 1 shows Consolidated Standards of Reporting Trials (CONSORT) flow chart of the study.

Setting
We will run this trial in six academic centres located in child and adolescent public hospitals in France. All centres have a unit for ASD diagnosis and assessment and a distinct unit for intervention where therapists have been trained in PACT and can provide PACT via videoconferencing. The parents receiving intervention come from a French-speaking population including socioeconomically disadvantaged groups.

Patient and public involvement
Alloisio (Association AAA https://autisme-ambition-avenir.com) and Belkhayat (association https://bleunetwork.fr/pro) are parents of a child with autism and represent two different association. They are part of the steering committee.

Population
Inclusion criteria
Children will be included if they meet the following criteria: (1) aged between 18 and 36 months old at referral, (2) meet criteria for ASD using the two gold-standard instruments ADOS-2 and ADI-R (Autism Diagnostic Interview-Revised). For inclusion into the study, the severity score comparison (CSS) on ADOS-2 will be greater or equal to 4. The score on the ADI-R algorithm...
for toddlers will be greater or equal to 11. The diagnosis will be confirmed by a multidisciplinary team trained in ASD assessment and diagnoses based in the academic departments of the hospitals, (3) have a non-verbal age equal to or above 12 months on the Mullen Scale of Early learning (MSEL) and (4) live more than 40 min away from a Centre for Resources in Autism (regional centre).

Referred parents will be included if they meet the following criteria: (1) speak French with their children (2) are able to use videoconferencing methods with therapists who will be based at the centre (assessed through the conduct of the Vineland Assessment Behavioural Scale by videoconferencing) (see online supplemental appendix 1)

**Exclusion criteria**

Exclusion criteria for the child will include:

i. A twin brother or sister with ASD or a brother or sister already included in the study.

ii. Diagnosed with epilepsy requiring medication.

---

Figure 1  CONSORT flow chart of the study. BOSCC, Brief Observation of Social Communication Change; CONSORT, Consolidated Standards of Reporting Trials; DCMA, Dyadic Communication Measure for Autism; PACT, Preschool Autism Communication Trial; TAU, treatment as usual.
iii. Severe hearing or visual impairment.
iv. An identification of a genetic anomaly which may impact on their ability to participate in the intervention or on data validity (determined by the principal investigator on a case-by-case basis).

Exclusion criteria for the referred parents (at least one parent with) will include:
i. Severe hearing or visual impairment.
ii. Severe psychiatric disorder.
iii. Unstable somatic disorders preventing participation in the intervention.
iv. Lack of internet provision.
v. Not available for regular intervention and follow-up.
vi. Opposition of one parent to the child’s participation in the study.
vii. Currently undertaking PACT therapy.

**Intervention conducted in the experimental group**

**Eligibility criteria for PACT therapist and adherence**

Therapists delivering the intervention will include speech language pathologist (SLP), occupational therapists, clinical nurses, psychologists or child and adolescent psychiatrists, all specialised in ASD. The therapists have already received formal training and supervision in PACT from the team who developed this training.12 24 Fidelity to PACT therapy will be maintained by regular meetings between therapists of all centres, with scoring and feedback of videotaped therapy sessions obtained during the study.

**PACT treatment principles**

As previously described,17 parents will be trained, via videofeedback, to identify and set key strategies facilitating the sociocommunicative interactions between their child and themselves. Parents will also be encouraged to use PACT every day outside the training session at least half an hour a day. The therapy follows a six-staged approach based on child developmental progression and strategies for establishing fundamental skills for the sociocommunicative development. The first two stages aim to increase parent’s identification of child focus and interest, synchrony, responsiveness and sensitivity to the child interest and communication. The third and fourth stages are targeted towards developing expression and comprehension of the child by commenting and modelling language adapted to the child’s developmental level. Child communication initiation is also improved in the fifth stage through different strategies such as anticipation and routine. The last stage aims to develop conversation and expansion of language for verbal children. Progression from one stage to the next depends on predefined criteria.

Based on the protocol of the first PACT RCT, parents will receive 18 sessions of training in PACT with the therapist over the 12 months12 215. 1-hour session every fortnight for the first 6 months to learn PACT strategies followed by 1-hour session per month over the next 6 months to maintain the capacity of parents to deliver the strategies. Therapist will train only one parent per family and maintain fidelity to the therapy manual. The ‘referred parent’ will have to be designated before the randomisation of the child. If the referred becomes unavailable, the therapy will stop or will continue with the other parent if possible and this change will be reported.

**Parent training session with the professional via videoconferencing**

Before each session, the parent will be asked to send a 10min video of their interaction with their child to the therapist via a secure cloud link. During the videoconferencing session (as in face-to-face intervention), referent parent will begin with a 5min discussion about their progress since the last session. The therapist will then share his/her screen and watch the home-based 10min video together with the parent. Together the parent and therapist will identify, review and discuss specific clips that demonstrate accomplishment of therapy goals for the relevant stage of the PACT programme. The therapist’s role will be to guide parents to identify successful strategies and responses (ie, episodes of engagement and/or mutual sharing with their child). Parents will be supported to reflect on their role in enhancing interaction and to identify new intervention goals.

**Parent PACT implementation in daily life outside the therapy session**

At the end of each session, the therapist will support the parent in setting 2–3 new goals, based on the strategies identified during the session. The therapist will encourage the parent to practice the strategies for the next session and discuss opportunities to achieve these goals in daily routine at home for at least 30 min per day. Parents will be guided to embed PACT strategies in everyday routines across different contexts. As therapy progresses, parents will be asked to send 10 min home videos of daily routines in different contexts.

**TAU and two follow-up consultations on ASD and its management**

Regardless of group allocation, parents will receive TAU consisting of psychoeducation about ASD, management and educational support for nursery and preschool placement. Parents will be referred to any relevant care available in the community (eg, SLP, occupational therapist, educator, behavioural psychologist, psychiatrist). TAU received during the course of the study will be described in both groups.

Regardless of group allocation, a psychiatrist or a psychologist from each autism centre will provide two supplementary 45 min follow-up consultations conducted by videoconferencing at 3 and 6 months after inclusion. This consultation will be carried out by following an interview guide. Three thematic areas will be systematically discussed with the parents: ASD information, access to treatment in the community, support for school or nursery. These follow-up consultations will ensure that
parents of both groups receive homogeneous information on ASD and its management.

Avoidance of contamination
Currently, PACT is not widely implemented in the community in France, particularly in the rural areas. Any families who are currently in receipt of PACT intervention will be excluded from this trial. However, any PACT that might be received in the community as part of TAU will be recorded.25

Research assessors will be separate to the therapists and will be located and supervised separately in each centre.

Professionals conducting the follow-up consultations will not be trained in PACT therapy or be part of the research assessments.

Measures
Primary outcome
To assess autism severity
ADOS-2 is a semistructured, researcher–child interaction based, standardised observational assessment, in communication, play, imaginative skills and repetitive behaviours.26 27 It is a widely used scale in the field of ASD research with good psychometric properties, recommended for the diagnosis of ASD and assessment of core autistic symptoms.26 28

At baseline and follow-up assessment after 12 months, we will use only ADOS-2 module 1, for children who are 18 months of age and older children who use no or few words.

There is a good inter-rater reliability for module 1.27 Internal consistency Cronbach’s alpha coefficients was high in original study.27 This scale has also shown that it can measure change in autism severity.13 28

ADOS-2 is composed of different items scored 0–3 or 0–2. Item A1 codes the level of language, from the severity for ‘the child is using regular use of statements with two or more words’ (code 0) to ‘the child has no spontaneous use of approximate words or words’ (code 4). For children with no or limited language (A1 ≥ 3, the two items measuring language in the algorithm (item A3 speech abnormalities, item A5 stereotyped language) will be scored 3 (worst value) (see reference 12). The minimum overall ADOS-2 module 1 raw score will be 0 and the maximum score 42. A higher score means more autistic symptoms.

Our primary outcome will be the change between baseline and 12 months in the overall raw score in reciprocal sociocommunicative interactions and repetitive and restrictive behaviours in line with the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth version).26 29

Researchers will be trained to achieve recognised standards. Regular reliability meetings of all researchers will address any discrepant ratings to maintain researcher calibration.

Secondary outcomes
To assess social communication and interaction in the natural setting of parent–child interaction at home:
- Brief Observation of Social Communication Change (BOSCC).30
To assess dyadic communication in the natural setting of parent-child interaction at home:
- Dyadic Communication Measure for Autism (DCMA).24
To assess child cognitive development:
- Mullen Scale of Early Learning (MSEL).23
To assess child language development:
- Development of Expressive Language, (Développement du Langage de Production en Français, DLPF).31
To assess adaptive behaviour of the child:
- Vineland Adaptive Behaviour Scales second version (VABS-2).32
To assess Parent’s Stress, health, priorities and experience of the family:
- Autism Family Experience Questionnaire (AFEQ).33
- Parental Stress Index (PSI).34
- General Health Questionnaire35

To assess implementation of the intervention:
- PACT Fidelity Rating Scale.
- Number of PACT training sessions undertaken.
- Quality of videoconferencing during each session.
- Parent’s acceptability of videoconferencing and implementation of PACT at home (self-report on Likert-scale).
- Number of hours per day using PACT at home at 12 months.
- Parent’s qualitative PACT adherence coded with DCMA on a 12 min home child–parent interaction video.

Figure 2 shows schedule of enrolment, interventions and assessments. Online supplemental appendix 1 shows more detailed about assessment.

Participant’s timeline
Toddlers with a suspected ASD will be approached by health professionals with information about this study. The research recruitment team will meet with the family, complete the ADI-R during the first meeting, and confirm eligibility criteria. Complementary assessments, including ADOS, MSEL with the child and Vineland will be conducted by videoconferencing with the parent, to assess the criteria for eligibility. If toddlers and families meet the criteria for participation, parents will be informed about the study and possibility of an intervention using PACT or TAU based on randomisation. A written informed consent will be obtained if the parent/family agrees to participate in the study after 1 week of reflection (see consent form in online supplemental appendix 2).

The ‘referent parent’ used to refer to the parents who will engage with the PACT therapy will be decided before randomisation. Children will be subsequently randomised into the intervention or TAU group. Parents will be informed of the result of the randomisation

Table 1 Assignment of intervention

<table>
<thead>
<tr>
<th>Time point</th>
<th>Enrolment</th>
<th>T0 baseline</th>
<th>T1 6 months</th>
<th>T2 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility screen</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DSM-5 criteria</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADOS-2</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADI-R for toddlers</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonverbal skills MSEL</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adaptive behavioral level: VABS 2 coded based on an interview done by videoconferencing with parents</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2 Schedule of enrolment, interventions and assessments (SPIRIT). ADI-R, Autism Diagnostic Interview-Revised; ADOS-2, Autism Diagnostic Observation Scale-2; AFEQ, Autism Family Experience Questionnaire; BOSCC, Brief Observation of Social Communication Change; DCMA, Dyadic Communication Measure for Autism; DLPF, Développement du langage de Production en Français; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, fifth version; GHQ, General Health Questionnaire; PACT, Preschool Autism Communication Trial; PSI, Parental Stress Index; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; TAU, treatment as usual; VABS, Vineland Adaptive Behaviour Scale.

Assignment of intervention

Allocation sequence generation and randomisation

All eligible toddlers, with parental consent, will be assigned to the two study groups in a 1:1 ratio using the minimisation method with the following stratification factors: the centre, the children’s age, level of language (according to the ADOS2 scale) and gender. To ensure allocation concealment, a minimisation algorithm with a 0.90 random element will be used and known only to the statistician (AD). The randomisation will be centralised.

Blinding

Owing to the nature of the intervention, parents and PACT therapists cannot be blind to the allocation group.
PACT therapists will not be involved in ASD assessment and diagnosis. An assessor blind to the allocation group will administer every assessment. Data manager and biostatistician will be blinded to the allocation groups.

Data collection and management

Data collection

Data will be collected through standardised observations, parental questionnaires and interviews carried out by a researcher blind to the allocation. We will be particularly vigilant about the measurement accuracy of the first criterion of judgement as described in the paragraph on ADOS-2.

Participation retention and follow-up

Children of both groups will benefit from early diagnosis and assessment and will have the same follow-up evaluations over the 1-year study period in the respective study centres. Any discontinuation of study participation will be collected and recorded with the reasons.

Data management

The study data will be collected on a secure electronic case report form (eCRF) that will be available at each centre through an internet portal. No personal identifying information will be mentioned on the eCRF. Each subject included in the study will be assigned a unique identification number.

All study data will be stored securely in the Academic Hospital of Lyon. All electronic data will be secured on a password-protected laptop. Paper-based study documents will be stored in a secure filing cabinet at each centre. Access to these files will be limited to research staff involved in the study.

The eCRF will only include the data necessary for the analysis to be reported in a scientific publication.

Statistical analysis

Simple size calculation

On the basis of the findings of the PACT Trial, we have powered the study to be able to detect a difference in overall change on the ADOS score of 2 points. The group difference in mean change between baseline and month 12 was −1 point for ADOS social affect score (mean change=2.9, SD=3.9 in TAU group and mean change=−3.9, SD=4.7 in PACT+TAU group) and −0.5 points for ADOS restricted and repetitive behaviours score (mean change=2.9, SD=3.9 in TAU group and mean change=−3.9, SD=4.7 in PACT+TAU group). The pre-measure and post-measure were correlated at 0.67. Therefore, the most conservative values were fixed for ADOS SD and for correlation among the repeated measures from a single participant. A target of 238 subjects (119 subjects per treatment arm) was planned to be randomised in the trial. Assuming a two-point difference in favour of the PACT+TAU compared with TAU, an SD of 5, a correlation between subsequent visits of 0.5, a drop-out rate of 20% and a two-sided significance level of 0.05, the planned sample size would provide about 80% power for the study.

Feasibility of recruitment

A strong partnership with ASD orientation platforms recently implemented in France, a broad communication (meeting, mail, flyers) to healthcare professionals (Speech pathologist, Occupational therapist, therapist, paediatrician, general practitioner) family associations and other stakeholders will allow the trial team to reach the sample size within 2 years.

Statistical analysis

A full statistical analysis plan will be finalised prior to database lock. Statistical analysis and results will be reported at the 12-month endpoint in accordance with the CONSORT 2010 statement. No interim analysis will be scheduled. All the statistical analysis will be carried out according to the intention to treat principle using SAS statistical software (SAS Institute).

Baseline characteristics will be presented in each group. Summary statistics will be presented for process variables (number of PACT sessions, quality of videoconferencing per session, acceptability and satisfaction of PACT intervention, number of hours declared to be realised with the child) to show the feasibility and acceptability of PACT implementation in the intervention group.

The pattern of missing data will be investigated (number and mechanism of missingness). Missing data strategies can be applied, and sensitivity analysis of different strategies (simple or multiple imputation) will be conducted.

A repeated measures analyses will be used to test the effect of PACT intervention on overall ADOS module 1 score over the 12-month study period. A linear mixed model will be run with the overall ADOS score as the dependent variable and including time (baseline, month 12), treatment (TAU or TAU+PACT) and the interaction between treatment and time as fixed effects and patient as random effect. Model will be adjusted for stratification factors (centre, age, level of language (item A1 ADOS-2) and gender) and baseline variables that show evidence of treatment group imbalance. Time will be represented by dummy variable. Model assumption will be verified according to residual analysis. If most of the assumptions are not met, other alternatives such as transformation of ADOS overall raw score will be examined. Sensitivity analyses like complete case and per-protocol analysis will be performed to assess the robustness of the results to protocol deviations. In complete-case analysis, only patient with primary outcome documented will be analysed. In per-protocol participants who violate the protocol will be excluded from the analysis.

All the secondary outcomes, (overall total score of the BOSCC, communication initiation and synchrony measured with the DCMA, overall raw score of the MSEL, in receptive and expressive language, overall score in expressive language of the DLPF, overall raw score of communicative and social of the VABS, PSI, Parent General Health score, AFEQ score) will be analysed in a similar way using with appropriate linear or generalised
linear mixed models. Tobit models will be used to address potential floor effects.

We will finally explore the parent’s and children’s characteristics, moderating the implementation and efficacy of this therapy. We will also test the previously described mediators implicated in the efficacy of this therapy.\(^\text{14}\)

**Qualitative analysis of barriers and facilitators of implementation**

Based on parents and of the therapist’s reports, we will describe the facilitators and barriers of the implementation of video-conferencing PACT.

The data will be collected through semistructured interview and will be analysed with the classical technique of Interpretative Phenomenological Analysis.\(^\text{36}\) Population selection will follow the rules of the purposive sampling and will allow a maximal variation of the sample.\(^\text{35}\) An estimation of 30–60 parents will be necessary to reach data saturation based on previous studies.\(^\text{38–40}\) The total number of therapists (around 7–8) will be interviewed. During the 40–60 min interview, we will explore the barriers and facilitators to implementing PACT by video-conferencing. A guide for the interview will be elaborated in the initial phase of the project based on first interviews. Interviews will be recorded and transcribed before analyses.

Data from the quantitative and qualitative sources in the process evaluation will be analysed separately. The results of the qualitative study will be integrated with the quantitative results to optimise the findings.\(^\text{41}\)

**Monitoring**

M-MG (IP) investigators associated, methodologists, statistician, parent representatives and associate researcher composed the trial steering committee (TSC). The TSC is independent of sponsor and funders and have no
competing interests. The TSC has developed the study protocol and is responsible for data collection, management, publications and the final data set.

The coordinating centre is independent from the centres for investigation.

According to the French law, the study requires formal data monitoring undertaken by the sponsor. Annual reporting will be completed and submitted to the funders.

Adverse events

Based on results from previous PACT intervention trials, no specific harm from trial participation is anticipated. However, as required by the French law, adverse events will be collected throughout the study and reported in the eCRF section. Description of the event, date of occurrence, intensity, severity, accountability will be reported. Outcomes of this event and action taken after its report will also be concealed.

We anticipate that the early assessment, follow-up consultation on ASD and its management will help and support both groups during the postdiagnosis period. Hence, no post-trial care is planned.

Trial status

The trial status is currently Recruiting. The study has started the 30 June 30, 2020. The anticipated end date will be 30 June 2023.

Figure 3 shows WHO trial registration data set. Online supplemental appendix 3 shows Standard Protocol Items: Recommendations for Interventions Trials Checklist.

Ethics and dissemination

This study (protocolV.5, date: 25 October 2019) is approved by the French National Review Board (reference No 2018-A02516-49). The results will be disseminated via peer-reviewed journals. It will also disseminate via national and international, general and specialist meeting and through the parent association (https://bleunetwerk.fr; https://autisme-ambitionavenir.com; desailespourgrandir.org). An individual feedback to the participant will be done through a regular newsletter. We will adhere to defined authorship criteria as per the International Committee of Medical Journal Editors.

Author affiliations

1Academic department of Child and adolescent neurodevelopmental psychiatry, Hospital Centre Vatinatier, Bron, France
2Research on Healthcare Performance (RESHAPE), INSERM U1290, Universite Claude Bernard Lyon 1, Lyon, France
3Pôle de santé publique, Hospices Civils de Lyon, Lyon, France
4Child and Adolescent Psychiatry, Centre Hospitalier Charles Perrens, Bordeaux, France
5Service Universitaire de Psychiatrie de l’Enfant et de l’Adolescent, Centre de Ressources Autisme Midi-Pyrénées, University Hospital Centre Toulouse, Toulouse, France
6Service Universitaire de Psychiatrie de l’Enfant et de l’Adolescent, Centre Hospitalier de Versailles, Le Chesnay, France
7Center of resources in Autism and Center of Excellence in Autism and Neurodevelopment disorders, University Hospital Centre Montpellier, Montpellier, France
8UVSQ, Inserm, CESP, “DevPsy”, Paris-Saclay University, Villejuif, France
9Department of Child and Adolescent Psychiatry, Hopitaux universitaires de Strasbourg. Strasbourg, France
10CNRS UPR 3212 - Team 9, University of Strasbourg, Strasbourg, France
11Centre de Soins Psychotherapeutiques de Transition pour Adolescents, Argeteuil Health and Social Services Centre, Lachute, Quebec, Canada
12Centre of Research in Epidemiology and Statistics, ECSTTRA Team UMR-1153, INSERM, Université de Paris, Paris, France
13The University of Manchester, Manchester, UK
14Division of Neuroscience and Experimental Psychology, Faculty of Biological Medical & Health Sciences, The University of Manchester, Manchester, UK
15Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust, Manchester, UK

Collaborators

Mrs Pauline Auphan (psychologist), Mrs Laetitia Bouveret (research assistant), Mrs Laurie Herman (research assistant), Dr Anne-Laure Tourellie (PACT trainer), Mrs Lucie Jansen (PACT trainer), Dr Sandrine Sonié (CRU Lyon), Pr Mario Speranza (CHU Versailles), Pr Bruno Fallisard (Paris), Pr Nicolas Georgieff (Lyon), Dr Matias Wintzer (HCL), Mrs Nadège Alloisio (parent association), Mr Chams-Dine Belkhayat (parent association).

Contributors

M-MG and ST, PO, LJ conceived and design the project, and M-MG is leading the coordination of the trial. M-MG, LJ and PO drafted the protocol and procured the project funding. LJ and M-MG are responsible for study implementation, staff training and supervision. PO, ST, AD and AZ contributed to the sample size calculation, the randomisation procedure and the statistical plan, and are responsible for data management, randomisation and statistical analysis. JG contributed to the protocol and paper writing. AR-L contributed to the protocol of the qualitative study. CA and NG to the PACT training and supervision of the team. M-MG, M-JO, LJ, AA, AJ, AB, CS, TM, TO are responsible for recruitment and evaluation of children. SG contributed to draft the paper. All authors critically reviewed and approved the final version of the manuscript.

Funding

This study is supported by a grant from the Programme Hospitalier de Recherche Clinique inter-régional Rhône Alpes (PHRCi-15-065) from the AURA region and a grant by the Caisse Nationale de solidarité pour l’autonomie (CNSA) as part of the call for projects launched for InesP (Institut de Recherche en Santé Publique) in 2016 in collaboration with the Institut national de la santé et de la recherche médicale (Inserm) (IrESP-17-Autisme3-16). The funders and sponsor (CH le Vinatier, 95, boulevard Pinel, France) have no role in study design, data collection, management, data analysis and interpretation of data, in the writing of the report or in the decision to submit the manuscript for publication.

Competing interests

None declared.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Marie-Maud Geoffray http://orcid.org/0000-0002-5528-3613

REFERENCES


Open access


Appendix 1: Secondary outcomes

The secondary outcomes are measured using standardized coding assessments of naturalistic observational videos (BOSCC, DCMA), performance-based standardized tests (MSE L), and parent-report-based standardized tests (VABS, DLFP, AFEQ, ISP, GHQ).

To assess social communication and interaction in the natural setting of parent-child interaction at home

Brief Observation of Social Communication Change (BOSCC) measures the same construct as the ADOS. It is a researcher coding assessment of autism symptoms based on child-adult interaction. It has good fidelity and results showed good construct validity [1]. The validity to measure the change was analysed in two small populations (N=20-50) and will have to be reanalysed in further trials [36,37]. It has the advantage to allow measure Dyadic interaction across different contexts. It was translated and retro-translated for the purpose of a previous study [2].

The scale is composed of 12 items scored from 0 to 5 according to the BOSCC algorithm. There is an overall score of 0 to 60 measuring core autism symptoms. A higher score indicates more autistic symptoms.

In the current study, a 12 minutes home-video will be recorded by the parents themselves. The parent will be provided with a simple protocol to follow using a standardized set of toys. The standardized set of toys given to the families at each time of assessment will include a cause and effect toy, shape sorter or puzzle, construction toys, miniature pretend play. The protocol includes 10 minutes time of natural play with children with the set of standardized toys and 2 minutes with bubbles play. A first unscored videotape would be done on the center (at T0) to train the parents to video record based on the protocol. In the week following, the parent will videotape at home a child-parent interaction according to the protocol with the standardized set of toys and send the video to the researchers via a secure platform. Professional may make up to two further requests if the video received is judged to not be of adequate quality. If the parent isn’t able to send a usable video according to the protocol, the researcher completes a home visit to demonstrate and help the parent to do the video the third time. Two further videos will be done at home at 6 months (T1) and 12 months (T2) in order to assess Social communication interaction in a naturalistic setting.

All the video will be scored by trained researchers.

The same parent called the “referent parent” will be videotaped by a relative at each time of assessment. He/ she will be identified before the randomisation. It will also be the parent who receive PACT therapy if in the group of PACT intervention.

To assess dyadic communication in the natural setting of parent-child interaction at home

The Dyadic Communication Measure for Autism (DCMA) is a direct observation instrument of the communication between a parent and a child with autism [3]. It rates parental and child mutual shared attention, child communication (initiation and response) and parental communication style (synchronous/asynchronous).
Independent inter-rated reliability on synchrony has been reported and is good [3]. It was translated and retro-translated for the purpose of a previous study [2].

It can be used to code a number of acts of communication per timepoint. A higher score indicates better communication.

Coding will be done on the same 12 minutes home parent-child video described above in BOSCC at baseline, 6 months and 12 months.

To assess child cognitive development

The *Mullen Scales of Early Learning (MSEL)* is a direct observation standardized tool from birth to 68 months [4]. It measures verbal and non-verbal skills of the children, according to the success or failure in tasks of the MSEL protocol delivered by a trained researcher. The MSEL has been used extensively as a discriminative and evaluative measure in children with autism spectrum disorder, Fragile X syndrome, and speech delays [5–7].

The MSEL will be assessed on the center before the inclusion and at 12 months.

Internal consistency and concurrent validity are good [4]. It was translated and retro-translated for the purpose of a previous study [2].

The MSEL includes 124 items that measure five specific domains: 1) Gross Motor; 2) Fine Motor; 3) Visual Reception; 4) Expressive Language; and 5) Receptive Language. Scoring varies by item from 2-point scale (0 = does not meet criteria to 1 = meets criteria) to a 6-point scale. Results for each scale are described by T scores (M = 50, SD = 10), percentile ranks, and age equivalents. Four cognitive scales (Visual Reception, Fine Motor, Receptive Language, and Expressive Language) sum to represent an Early Learning Composite Score which measures overall cognitive functioning (M=100, SD=15). A higher score means better skills. This evaluation will be realized before inclusion and at 12 months.

To assess child language development

The “development of expressive language”, a standardised French Scale (Development du Language de Production In french_DLPF), is based on a self-administered parent-report [8]. This measure is standardised for age. Only the level 4 of the DLPF will be administered at each assessment to have a continuous score on expressive language. The DLPF was validated in a study [3]. Score is calculated based on the number of words in the naturalistic environment of the child as reported by the parents. A higher score means better language skills. This questionnaire will be completed by the referent parent at baseline and at 12 months.

It will complete the measure of functional communication with VABS-2 and standardised measure with MSEL.

Adapative behavior

Vineland Adaptive Behaviors Scales second version (VABS-2) is a parent reported scale to measure the child’s daily personal and social skills [9]. This measure will be collected via a parental interview over videoconferencing before the inclusion and at 12 months. Videoconferencing model has been chosen...
in our study to avoid multiples visits on the centre but also to evaluate, before the inclusion, if a long videoconferencing meeting could be done with the family on a technical point of view. A first assessment will be proposed to the parents. In case of technical difficulties during the first meeting, a second, and if necessary, a third meeting will be proposed. Tips to improve videoconferencing will also be provided to the parents. In case of failure of every remote assessment, the family will be considered as not eligible for the study as the remote PACT session require the ability to conduct a videoconferencing meeting.

This measure will provide an estimate of any assesses functional change in socialization, communication, motor and daily living skills, based on parent observation in the naturalistic settings of the child.

The VABS has well-established psychometric properties [9,10]. It is validated in french.

All of the items are rated on a three-point Likert scale, ranging from ‘0’ (seldom or never present) to ‘2’ (always present). Results for each scale are described by t scores (M = 50, SD = 10). An overall score is described by normalized score (M=100, SD=15). The range for each subscale is from 20 to 140. The subscales are summed to compute a total score, ranging from 80 to 560. The higher the scores are, the better adaptive functioning the children achieve.

To assess Parent’s Stress, health, priorities and experience of the family

The psychometry of the following tools are described in the manual of each tool.

Autism Family Experience (AFEQ) [11] is a 48-item self-administered parent report about quality of life and priorities for early intervention. It is composed of 4 subscales: experience of being a parent (range 13-65), family life (range 9-45), child development understanding and relationships (14-70), child symptoms (12-60). The sum of all domains gives the total score (range 48 - 240). Each question is assessed using a 5-point Likert scale. Scores range from “always” (1) to “never" (5)”. It was translated and retro-translated for the purpose of this study with the author. For the total score and the domain scores a higher score indicates a lower outcome. This questionnaire will be completed by the referent parent at baseline and at 12 months.

ISP (Parental stress index) is a 36-item self-administered parent report to measure the stress in the parent–child system. The PSI consists of three subscales: Parental Distress, Parent–child Dysfunction Interaction, and Difficult Child. Each subscale consists of 12 items rated from 1 (strongly agree) to 5 (strongly disagree), with subscale scores ranging from 12 to 60. The three domains combined form a Total Stress score (with a total score ranges from 36 to 180). We will use the short form of the 4th edition. A validated French version exists [12]. A higher score on the subscales and total stress score indicates increased levels of stress. This questionnaire will be completed by the referent parent at baseline and at 12 months.

General Health Questionnaire (GHQ-28) is a self-administered parent report, 28 item scaled version, assessing somatic symptoms, anxiety and insomnia, social dysfunction and severe depression. Each item is rated according to a Likert score method (1 to 4). The GHQ-28 global score range from 36 to 110 [13]. A higher score means more health problems. This questionnaire will be completed by the referent parent at baseline and at 12 months.
To assess implementation of the intervention

Professional adherence to the treatment:

All therapy training sessions with professionals will be videotaped and will be independently rated by the lead therapist using the PACT Fidelity Rating Scale (of the PACT manual) at regular intervals across the trial period. The PACT Fidelity Rating Scale measures how the therapists follow the PACT manual including the style of training.

Acceptability and feasibility of the PACT session

The therapist will collect the number of the session done with each parent. The quality of videoconferencing during each session with the professional will be rated. Quality of sound and quality of the image will be rated with a 4-points Linkert scale. The number of disconnections along the session will also be collected.

The parents will self-report (likert-scale) the acceptability of videoconferencing training and implementation of PACT at home.

Parent PACT adherence at home

At 12 months, Parents will declare the average number of hours per day using PACT at home outside the PACT session with the therapist.

DCMA, coded on the 12 minutes home child-parent interaction will measure the parent’s qualitative adherence of PACT intervention.


Formulaire de recueil de consentement de participation à une recherche

Titre : Efficacité sur la sévérité des signes autistiques du jeune enfant avec un trouble du spectre autistique d'une intervention développementale conduite par les parents formés par visioconférence (IFPAD).

Investigateur coordonnateur : Dr Marie-Maude GEOFFRAY
Promoteur : CH Le Vinatier
95 Boulevard Pinel
69677 BRON CEDEX

Je soussigné représentant légal n°1 : NOM et Prénom : __________________________________
Je soussigné représentant légal n°2 : NOM et Prénom : __________________________________
De l’enfant : NOM et prénom du mineur : _____________________________________________
Né(e) le :        /     /      à (ville et code postal) : __________________________________________
Demeurant : ____________________________________________________________________

Déclare : que le Dr ____________________, nous a proposé de faire participer notre enfant à l'étude sus nommée,
- qu'il nous a expliqué en détail le protocole,
- qu'il nous a notamment fait connaître :
  • L'objectif, la méthode et la durée de l'étude
  • Les contraintes et les risques potentiels encourus
  • mon droit de refuser de participer et en cas de désaccord de retirer mon consentement à tout moment
  • notre obligation d'inscription à un régime de sécurité sociale pour mon enfant
  • que, si nous le souhaitons, à son terme, nous serons informés par le médecin investigateur de ses résultats globaux
  • que le comité de Protection des Personnes Sud-est III a émis un avis favorable en date du 30/10/2018 et a accepté l'amendement de la version N° 5 du protocole en date du 25 octobre 2019.
  • que l’ANSM a été informée de la mise en place de cette étude
  • que dans le cadre de cette étude le promoteur, le CH le Vinatier, a souscrit à une assurance couvrant cette recherche : Assurance SHAM, 18 rue Edouard Rochet, 69372 LYON CEDEX 08
- que nous avons répondu en toute bonne foi aux questions concernant l'état de santé de notre enfant et sa participation à d'autres études.

Les informations relatives à l’étude recueillies par l’investigateur sont traitées confidentiellement. J’accepte que les données enregistrées au cours de l’étude puissent faire l’objet d’un traitement informatisé conformément à la méthodologie MR001 de la Commission Nationale de l’Informatique et des Libertés (CNIL). Nous avons pris connaissance que le Centre Hospitalier Le Vinatier est responsable de nos informations personnelles recueillies dans le cadre de l’étude IFPAD et que ces informations peuvent être conservées pendant 15 ans. Nous avons bien noté que nous disposons d’un droit d’accès et de rectification, d’effacement et d’opposition au traitement des données nous concernant à tout moment de l’étude auprès du Centre Hospitalier Le Vinatier – Service de la Recherche - BP 300 39 – 95 bd Pinel
69 678 Bron cedex
du Dr GEOFFRAY, 04.37.91.52.56 ou auprès du responsable de la protection des données du CH Le Vinatier en le contactant à l’adresse mail : fabien.joubert@ch-le-vinatier.fr ou par téléphone au 04.37.91.54.40, dans le respect de la loi « informatique et liberté » (loi du 6 janvier 1978) et du règlement Général à la protection des données (RGPD) entré en vigueur le 25 mai 2018.

Si nous ne sommes pas satisfaits des réponses que nous avons obtenues, nous pouvons nous adresser à la Commission Nationale de l’Informatique et des Libertés (CNIL) en utilisant le lien : https://www.cnil.fr/

Nous pouvons également contacter les médecins suivants : Dr GEOFFRAY, 04.37.91.52.56 en cas d’événement indésirable et pour tout renseignement concernant ma participation à l’étude et en cas de problème médical survenu pendant l’étude.

Après avoir discuté librement et obtenu réponse à toutes nos questions, nous acceptons librement et volontairement de faire participer notre enfant à cette recherche dans les conditions précisées dans le formulaire d’information et de consentement.

<table>
<thead>
<tr>
<th>Nom et prénom du représentant légal n° 1</th>
<th>Nom de l’investigateur :</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature précédée de la mention « lu et compris »</td>
<td>Date : / / Signature :</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nom et prénom du représentant légal n° 2</th>
<th>Date : / / Signature :</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature précédée de la mention « lu et compris »</td>
<td>Nom de l’investigateur :</td>
</tr>
</tbody>
</table>

Document réalisé en 2 exemplaires originaux (dont le premier doit être gardé 15 ans par l’investigateur, et un autre remis aux parents).
## SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Administrative information</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>12 (fig 3)</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>13</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>13</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>13</td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Background and rationale</td>
<td>6a</td>
<td>Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>6b</td>
<td>Explanation for choice of comparators</td>
<td>3</td>
</tr>
<tr>
<td>Objectives</td>
<td>7</td>
<td>Specific objectives or hypotheses</td>
<td>4</td>
</tr>
<tr>
<td>Trial design</td>
<td>8</td>
<td>Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)</td>
<td>4</td>
</tr>
</tbody>
</table>

*SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.*

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open doi: 10.1136/bmjopen-2020-044669.
### Methods: Participants, interventions, and outcomes

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study setting</td>
<td>4</td>
</tr>
<tr>
<td>Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained</td>
<td>9</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>5</td>
</tr>
<tr>
<td>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)</td>
<td>10</td>
</tr>
<tr>
<td>Interventions</td>
<td>6</td>
</tr>
<tr>
<td>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered</td>
<td>11a</td>
</tr>
<tr>
<td>Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)</td>
<td>11b</td>
</tr>
<tr>
<td>Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)</td>
<td>11c</td>
</tr>
<tr>
<td>Relevant concomitant care and interventions that are permitted or prohibited during the trial</td>
<td>11d</td>
</tr>
<tr>
<td>Outcomes</td>
<td>8</td>
</tr>
<tr>
<td>Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended</td>
<td>12</td>
</tr>
<tr>
<td>Participant timeline</td>
<td>9 (fig 2)</td>
</tr>
<tr>
<td>Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)</td>
<td>13</td>
</tr>
<tr>
<td>Sample size</td>
<td>10</td>
</tr>
<tr>
<td>Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations</td>
<td>14</td>
</tr>
<tr>
<td>Recruitment</td>
<td>11</td>
</tr>
<tr>
<td>Strategies for achieving adequate participant enrolment to reach target sample size</td>
<td>15</td>
</tr>
</tbody>
</table>

### Methods: Assignment of interventions (for controlled trials)

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation:</td>
<td>9</td>
</tr>
<tr>
<td>Sequence generation</td>
<td>16a</td>
</tr>
<tr>
<td>Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions</td>
<td></td>
</tr>
</tbody>
</table>
Allocation concealment mechanism 16b  Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Implementation 16c  Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions

Blinding (masking) 17a  Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how

  17b  If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial

Methods: Data collection, management, and analysis

Data collection methods 18a  Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

  18b  Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

Data management 19  Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol

Statistical methods 20a  Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol

  20b  Methods for any additional analyses (eg, subgroup and adjusted analyses)

  20c  Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

Methods: Monitoring

Data monitoring 21a  Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
<table>
<thead>
<tr>
<th>Section</th>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
<td>21b</td>
<td>12</td>
</tr>
<tr>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td>22</td>
<td>12</td>
</tr>
<tr>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
<td>23</td>
<td>13</td>
</tr>
<tr>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
<td>24</td>
<td>13</td>
</tr>
<tr>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
<td>26a</td>
<td>13</td>
</tr>
<tr>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
<td>26b</td>
<td>NA</td>
</tr>
<tr>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>27</td>
<td>13</td>
</tr>
<tr>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>28</td>
<td>13</td>
</tr>
<tr>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>29</td>
<td>14</td>
</tr>
<tr>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation</td>
<td>30</td>
<td>12</td>
</tr>
<tr>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions</td>
<td>31a</td>
<td>13</td>
</tr>
<tr>
<td>Authorship eligibility guidelines and any intended use of professional writers</td>
<td>31b</td>
<td>13</td>
</tr>
<tr>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code</td>
<td>31c</td>
<td>14</td>
</tr>
</tbody>
</table>
Appendices

<table>
<thead>
<tr>
<th>Informed consent materials</th>
<th>32</th>
<th>Model consent form and other related documentation given to participants and authorised surrogates</th>
<th>App 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biological specimens</td>
<td>33</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable</td>
<td>NA</td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.*